The biopharmaceutical company has extended its series C round with funds from investors including Roche.
UK-based biomedical company Horizon Discovery closed a £11.3m ($18.6m) series C round of funding on Thursday from investors including Roche Venture Fund, the corporate venturing division of pharmaceutical conglomerate Roche.
Roche became a backer of Horizon when they acquired existing investor, the biotech firm Genentech, in March 2009, around the same time Genentech invested an undisclosed amount in Horizon. Roche subsequently provided funding in November 2009 and September 2010.
Venture capital firm MVM Life Sciences led the latest round,…
